@adrianakahn.bsky.social @maryamlustberg.bsky.social #SABCS25 #bcsm

🔍HER2 PARADIGM Trial now enrolling
🔹HER2-0 and HER2-0+ pts with MBC
🔹s/p 1 line of therapy
➡️T-DXd until progression
🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample
NCT06750484
Love working with this outstanding
Yale Breast & @yalepathology.bsky.social team!
@yalecancer.bsky.social

🔹highest risk >6% 5 yr; high penetrant variant: mammo alt MRI q6 m
🔹elevated risk 2.5 risk percentile by age: annual mammo + RRcounseling
🔹average risk: biennial mammo
🔹low risk 40-49 yrs & <1.3%: no screening until >1.3% or 50 yrs
#bcsm

🚨Wisdom Trial🚨
🔹randomized women to risk based bca screening vs annual screening
📍risk based: 9 genes, PRS, BCSC v2 model➡️ 4 risk groups guided frequency of screening
✅ rate of stage IIB ca noninferior to annual screening
🔹rate of breast biopsies was not lower
#SABCS25

📣lidERA trial📣
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25

💭How do we approach 1L HER2+ MBC in the context of H‬ER2CLIMB05, DB-09, & PATINA?
‪ 🔍 Tune into #TumorBoardTuesday 12/16‬ where we discuss!

🚨HER2CLIMB05 🚨
🔹Pts HER2+ MBC s/p THP x 4-8 cycles ➡️ HP + tucatinib vs HP
🔹PFS 24.9m vs 16.3m p<.0001
🔹HR- 24.9m vs 12.6m
🔹HR+ 25m vs 18m
⚠️ Increase in diarrhea and hepatic AEs
🔹Control arm had inferior PFS when compared to DB-09 control arm
#SABCS25 #bcsm

Powerful message from Dr. Amy Beumer at #SABCS25: It’s time to “fix the toxic friendship” and design dosing with patients—balancing side effects, quality of life, and longevity. @maryamlustberg.bsky.social @sabcs.bsky.social

📌Starting #SABCS25 off with a discussion of the Advanced Breast Cancer (ABC) Global Decade Report 📈
🔸improved 5 year OS 26% ➡️33%
🔸improvement in QOL, but 79% report negative QOL
🔸access to care gaps have widened
✅ 10 goals 2025-2035
#bcsm @maryamlustberg.bsky.social

💡Phenomenal @onclive.bsky.social Fellows Forum ahead of #SABCS25 presenting important research, learning about advancing our careers, and making connections with the future leaders in breast oncology 🤝 thankful for the opportunity!@drsgraff.bsky.social @brianato.bsky.social

📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing the goals of de-escalation in low risk, escalation in high risk, and individualized treatment in intermediate risk patients. Thankful for the opportunity to attend!✨#LSBC25 @luriecancer.bsky.social

💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management cans so much more ✨Thank you Lynn Sage for the travel award!💐 #LSBC25 @luriecancer.bsky.social

Excited to have joined Dr. Winer and Etienne to discuss medical oncology training, the future of oncology, and more! 🎙️🩺 @yalecancer.bsky.social

Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼‍♀️💨 @ctfride.bsky.social @yalecancer.bsky.social

A fundraising page for Nicole Casasanta Join the Closer to Free Ride on Saturday, September 6th. Register or donate at RideCloserToFree.org.

www.rideclosertofree.org/participants...

On September 6, 2025, I’ll be participating in the Closer to Free Ride to to raise funds to support cancer research and care for those who need it most - the patients, the families, and our team @yalecancer.bsky.social and Smilow Cancer Hospital Please consider donating to my ride!🚴🏻‍♀️

📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients

Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations

We have great representation in this morning's #ASCO25 poster session in Hall A! Stop by and support our presenters:
Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi.
@yaleschoolofmed.bsky.social

🔹60% dc T-DXd, 21% for AEs, 11% pt decision vs T 3.4% for AEs
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm

🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025

🔸 ctDNA+ TNBC pts after NAT strong predictor of recurrence HR 9.5 CI 2.6-35 p=0.0006
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025

Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%

🔹Imbalance between lines of therapy makes interpretation challenging

Innovative SERENA-6 trial: at molecular progression switch to SERD w/ continuation of CDK4/6i in HR+ MBC improved PFS1✅
🔹PFS2 & OS not mature
🔹 Improved TTD in QOL
🔹Control group PFS still 9.2 m
🔹Awaiting data on clearance of ctDNA after switch
#ASCO2025

Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social

Looking forward to joining the research community investigating ADCs!✨ @yalecancer.bsky.social

Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025

INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt

#ASCO25 @ascocancer.bsky.social

In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g

#ASCO25 @ascocancer.bsky.social